Una nueva píldora reduce el riesgo de un segundo accidente cerebrovascular

Fuente: Time · salud · Estados Unidos, Estados Unidos

Una nueva píldora reduce el riesgo de un segundo accidente cerebrovascular

On November 9, the U.S. Food and Drug Administration (FDA) approved a new type of medication to reduce the risk of strokes in certain populations. Asundexian, which will be sold under the brand name Sunharbo, is a daily pill that is the first to target a specific factor in the blood-clotting process that can contribute to stroke. In a study submitted to the FDA by Bayer, researchers found that the drug, when combined with an antiplatelet therapy such as aspirin, reduced the risk of an additional stroke by 26% in just over a year compared to people who received placebo and the antiplatelet therapy. The drug is approved for people who have recently had an ischemic stroke, which occur when clots block blood flow to the brain, or a transient ischemic attack caused by a temporary blockage of blood flow to the brain that doesn’t cause permanent damage. Researchers have known for years that some people born with a genetically driven lower risk of stroke have lower levels of a compound involved in blood clotting, called Factor XIa, in their blood. It took more than a decade for scientists to turn that observation into a viable medication, says Dr. Christoph Koenen, chief medical officer at Bayer. But asundexian prevents small clots that may form in the vessels from becoming larger ones that can grow to block blood flow. One of the findings that most impressed the researchers was that 'it didn’t matter how old people were, from what part of the world, what their medical history was, or what type of ischemic stroke they had—all of the patients seem to benefit similarly from the treatment,' says Shoamanesh. Given the encouraging results in reducing the risk of recurrent strokes, Koenen says Bayer is exploring 'if there are other benefits of asundexian we can bring to different patient populations.'

También lo cubren: TIME.

🔗 Leer la noticia completa en Time

Ver más en NewsToday